Radius Health

Radius Health is a U.S.-based, commercial-stage biopharma company that has established itself in the bone health market with its lead product, TYMLOS, an anabolic agent for osteoporosis. The company expanded its portfolio in 2023 by in-licensing BINOSTO, an oral effervescent bisphosphonate, and is actively seeking further partnership and growth opportunities. In 2024, Radius Health became part of Paratek Pharmaceuticals, a strategic move that likely aims to combine resources and pipelines for enhanced scale and commercial reach in specialty therapeutics.

Legacy expertise in peptide chemistry and selective parathyroid hormone receptor (PTHR1) modulation for anabolic bone building, as demonstrated by abaloparatide (TYMLOS). Current strategy appears more focused on commercial execution and business development than a proprietary platform.

TYMLOS competes in the anabolic osteoporosis segment against teriparatide (Forteo), romosozumab (Evenity), and the upcoming oral anabolic agent. BINOSTO competes in the large but generic-dominated oral bisphosphonate market, where differentiation is based on formulation and tolerability. The merger places the company in competition with larger, more diversified pharmaceutical companies.